CASI Pharmaceuticals Inc.

04/03/2026 | Press release | Distributed by Public on 04/03/2026 14:31

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Wang Chunhua
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [CASIF]
(Last) (First) (Middle)
1701, CHINA CENTRAL OFFICE TOWER 1, NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Operating Officer
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
BEIJING 100025
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy) (1) 03/19/2028 Ordinary Share 20,000 $1.93 D
Option (right to buy) (1) 01/09/2030 Ordinary Share 8,000 $1.93 D
Option (right to buy) (1) 01/27/2031 Ordinary Share 2,000 $1.93 D
Option (right to buy) (1) 08/16/2031 Ordinary Share 40,000 $1.93 D
Option (right to buy) (1) 08/16/2031 Ordinary Share 20,000 $1.93 D
Option (right to buy) (1) 08/16/2031 Ordinary Share 40,000 $1.93 D
Option (right to buy) (1) 05/12/2033 Ordinary Share 16,667 $1.93 D
Option (right to buy) (1) 06/18/2034 Ordinary Share 7,500 $2.67 D
Option (right to buy) (1) 11/06/2034 Ordinary Share 30,000 $5.78 D
Option (right to buy) (1) 11/06/2034 Ordinary Share 20,000 $5.78 D
Option (right to buy) 05/12/2026 05/12/2033 Ordinary Share 8,333 $1.93 D
Option (right to buy) 06/18/2026 06/18/2034 Ordinary Share 7,500 $2.67 D
Option (right to buy) 06/18/2027 06/18/2034 Ordinary Share 7,500 $2.67 D
Option (right to buy) 06/18/2028 06/18/2034 Ordinary Share 7,500 $2.67 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Wang Chunhua
1701, CHINA CENTRAL OFFICE TOWER 1
NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT
BEIJING 100025
Chief Operating Officer

Signatures

/s/ Chunhua Wang 04/03/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The options are fully vested and exercisable as of the date of this form.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
CASI Pharmaceuticals Inc. published this content on April 03, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 03, 2026 at 20:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]